Cellectis S.A. (ALCLS)
Euronext
Closed
Aug 21, 2026
Day's Range
2.8652 wk Range
2.03Overview - ALCLS - Cellectis S.A.
Key Statistics
Valuation
Enterprise Value
104.73M
P/E (Trailing)
‪-4.11‬
P/E (Forward)
‪-1.81‬
PEG Ratio
‪-1.81‬
Price / Sales (TTM)
‪4.52‬
Price / Book
‪5.93‬
EV / EBITDA
‪-2.62‬
Profitability
Gross Margin
‪54.96%‬
Profit Margin
‪-102.33%‬
Operating Margin
‪-340.68%‬
Return on Assets
‪-11.66%‬
Return on Equity
‪-94.53%‬
Ownership
Shares Outstanding
100.69M
Float
46.78M
Held by Insiders
‪48.00%‬
Held by Institutions
‪10.42%‬
Price stats
Beta
‪2.75‬
50-Day Avg
‪2.58‬
200-Day Avg
‪3.24‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
1 analysts
Market Cap - ALCLS - Cellectis S.A.
Peers - ALCLS - Cellectis S.A.
Peer Comparison
Compared with companies in Biotechnology listed on Euronext.
Profile Summary - ALCLS - Cellectis S.A.
About
Cellectis S.A. is a clinical-stage biopharmaceutical company specializing in the development of next-generation immunotherapies for cancer. With over 25 years of innovation, Cellectis leverages its proprietary TALEN® gene-editing technology to engineer chimeric antigen receptor (CAR) T-cells, creating "off-the-shelf"…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
